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Abstract
Background: Carcinoid syndrome is associated with a reduced quality of life that can be attributed to symptoms
such as diarrhea and fatigue as well as social and financial issues. This study was conducted to psychometrically
assess meaningful change in bowel movement frequency among carcinoid syndrome patients using data from the
TELESTAR clinical study.
Methods: An anchor-based approach for deriving meaningful change thresholds consisted of mapping change
from baseline bowel movement frequency to other patient-reported assessments of change. These included
the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core
Questionnaire (QLQ-C30) Diarrhea Symptom responders, the EORTC Gastrointestinal NET questionnaire (GI.NET21) GI
Symptom responders, and reported adequate relief at Week 12 (≥ 10-point score decrease from Day 1 to Week 12).
Parameters included within-group mean change from baseline to Week 12, t-tests of the change (Wilcoxon rank sum
for adequate relief), and effect size.
Results: There were 135 carcinoid syndrome patients with a mean baseline frequency of 5.7 bowel movements a day.
A distribution-based method yielded meaningful change estimates of 0.62 bowel movements a day for overall
frequency and 0.83 bowel movements a day at Week 12. Anchor-based analysis indicated a large effect size among
patients who reported adequate relief at Week 12 (− 1.58; n = 18; P = 0.014), the QLQ-C30 Diarrhea domain responders
(− 1.24; n = 40; P < 0.001), and the GI.NET21 GI Symptoms Domain responders (− 1.49; n = 25; P = 0.005). Exit interview
data for meaningful change yielded effect size estimates of − 1.57 for overall change during the Double-blind
Treatment Period and − 1.97 for change between Baseline and Week 12.
Conclusions: Meaningful change derivation is critical to interpret patient outcomes for evaluating treatment efficacy.
In this study, carcinoid syndrome patients experienced clinically meaningful reductions in bowel movement frequency
of ≥30% over 12 weeks with telotristat ethyl treatment.
Trial registration: NCT01677910.
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Introduction
Carcinoid tumors are well-differentiated neuroendocrine
tumors (NETs) that originate in neuroendocrine cells [1].
Advanced disease is associated with a reduced health-
related quality of life (HRQoL) related to diarrhea, fatigue,
and flushing symptoms, besides family, social, and finan-
cial issues [2–5]. These NETs usually occur in the small
intestine and represent about 0.5% of all newly diagnosed
malignancies with an annual incidence of approximately 2
per 100,000 persons [6, 7]. The overall 5-year survival rate
is 67.2% [6]. Carcinoid syndrome (CS) is caused by
bioactive compounds released into the circulation, occur-
ring in almost 20% of NETs patients [8]. Large amounts of
serotonin (5-hydroxytryptamine [5-HT]) release is be-
lieved to cause diarrhea, endocardial and mesenteric fibro-
sis [9–11].
The TELESTAR study was conducted to psychometric-
ally assess meaningful change in bowel movement (BM)
frequency and evaluate the efficacy and safety of telotristat
ethyl in CS patients with diarrhea not adequately con-
trolled by somatostatin analogs (SSA) (TELESTAR study;
NCT01677910). The primary objective of TELESTAR was
to confirm that at least 1 or more doses of telotristat ethyl
was effective in reducing the number of daily BMs from
baseline averaged over the 12-week double-blind period
(Treatment Period) [12].
Methods
Study design
The design and results of TELESTAR have been previ-
ously described [13]. Briefly, patients entered a Screening/
Run-in Period of 3- or 4-weeks to establish Baseline symp-
toms. They were then randomly assigned (1:1:1) on Day 1
to receive one of two dose levels of telotristat ethyl (250 or
500mg) or placebo thrice daily for 12 weeks. All patients
remained on their baseline dose of SSA therapy during
the Treatment Period. Subsequently, they participated in a
36-week Open-label Extension Period when everyone re-
ceived 500mg of the active study drug thrice daily. This
study received Institutional Review Board approval.
The focus is on the primary endpoint, change from
Baseline in BM frequency during the Double-blind
Treatment Period. The intent-to-treat (ITT) analysis
population included all randomized patients. All analyses
populations were derived from the ITT dataset. All pa-
tients participating in the patient interview substudy
after the Double-blind Treatment Period were included
in the patient interview subpopulation (ISP).
Study instruments
Evaluation of meaningful change in BM frequency re-
quired the inclusion of other supportive clinical outcomes
assessments: a Yes/No question about CS gastrointestinal
symptom relief; European Organization for Research and
Treatment of Cancer (EORTC) Quality of Life Ques-
tionnaire - Core Questionnaire (QLQ-C30) and EORTC
Gastrointestinal NET questionnaire (GI.NET21) scales;
and patient exit interview responses.
Number of daily BMs
Patients electronically recorded the number of daily
BMs. The average BM number was mapped to indi-
vidual analyses using the following criteria: difference
between average Baseline BM frequency and the over-
all average BM frequency; and the difference between
average Baseline BM frequency and average BM fre-
quency at Week 12.
EORTC QLQ-C30 and GI.NET21
The QLQ-C30 contained 30 questions incorporated into 5
functional domains (Physical, Role, Cognitive, Emotional,
and Social), 9 symptom scales (Fatigue, Pain, Nausea
and Vomiting, Dyspnea, Insomnia, Appetite Loss,
Constipation, Diarrhea, and Financial Difficulties), and
a single global HRQoL/Global Health Status score [14].
The GI.NET21 module contained 21 questions: 4
single-item assessments about muscle and/or bone pain,
body image, information, and sexual functioning, plus 17
items organized into 5 scales: Endocrine Symptoms (3
items), GI Symptoms (5 items), Treatment-related
Symptoms (3 items), Social Functioning (3 items) and
Disease-related Worries (3 items) [15].
Exit interviews
English- and German-speaking patients were invited to
participate in the exit interview study as prespecified in
the TELESTAR protocol [16]. All participants consented
to the interview procedure to be conducted within 2
weeks after they completed the 12-week Double-blind
Treatment Period or early termination. Patients were
categorized based on reported satisfaction with improve-
ment over the course of treatment (“very satisfied”;
“somewhat satisfied”; “neither satisfied nor dissatisfied”;
“somewhat dissatisfied”; or “very dissatisfied”). Patients
were also categorized according to perception of BM
frequency reduction (“a great deal better”; “much better”;
“a little better”; “the same”; “a little worse”; “much
worse”; or “a great deal worse”).
Analytic methods
Analyses focused on the derivation and evaluation of
thresholds to interpret meaningful change and respon-
siveness in BM frequency. All patients were included ir-
respective of receiving treatment (n = 90) or placebo
(n = 45). Analyses was conducted using SAS Version 9.3
or higher (SAS Institute, Cary, NC, USA) [17].
Meaningful change on a patient-centered endpoint re-
ferred to the smallest difference in scores in the domain
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of interest (e.g., symptom or functional score), which
patients perceived as beneficial. This could then be used
further to discriminate between treatment groups and
develop a thorough understanding of the HRQOL
impact of BM frequency reduction [18, 19].
Change in BM frequency from Baseline was used to
develop two individual distribution-based estimates: (1)
overall change from Baseline, defined as the difference
between average BM frequency during the Run-In
Period and average BM frequency during the Double-
Blind Treatment Period; and (2) change from Baseline at
Week 12, defined as the difference between average BM
frequency during the Run-In Period and 7-day average
BM frequency at Week 12. Distribution-based thresholds
were derived for both estimates independently using the
½ standard deviation (SD) rule [18], which is ½ the SD
of both estimates.
The anchor-based approach to derive meaningful
change thresholds consisted of mapping change from
Baseline in BM frequency to other patient reported
assessments of change. The relationship between BM
frequency and each continuous patient-reported out-
come (PRO) anchor was evaluated prior to inclusion in
the anchor based analysis using correlational analyses.
The criterion threshold value for determining if the an-
chor was correlated with the outcome is a correlation
coefficient > 0.30 at Baseline, Week 12, or change from
Baseline [18]. Anchor-based thresholds were developed
by calculating mean change and the associated effect size
(ES) statistic for each anchor-based. The ES was calcu-
lated from the difference between average score in BM
frequency over 12 weeks and average Baseline BM fre-
quency, this difference being divided by the SD of aver-
age Baseline BM frequency. A negative ES represented
BM frequency reduction compared to Baseline [19, 20].
An additional analysis was conducted, where ES was cal-
culated as the mean score in average BM frequency at
Week 12 minus the average Baseline BM frequency di-
vided by the SD of the group average Baseline BM fre-
quency. For both analyses, a single value (or range of
values for interpreting change in BM frequency) was de-
veloped for the full ITT population by selecting the
mean improvement for each analytic group. These
thresholds could be applied to stratify patients within
each treatment arm by mean change in BM frequency
relative to the identified threshold. Negative values of ES
indicated reductions from Baseline in BM frequency.
Responsiveness refers to the ability of an assessment
to detect change where it exists [18]. To assess respon-
siveness, patients were defined as improved or worsened
based on meaningful change in prespecified categorical
endpoints. An absolute improvement of 10 points from
Day 1 to Week 12 defined improvement in each of the
EORTC domains [20]. The analysis of covariance
(ANCOVA) procedure was used to calculate the P-value
and adjusted for age, sex, and race. The within-group
level of change in individual scores was expressed as a
standardized effect size (SES), calculated as the mean
change score between Baseline and Week 12, and di-
vided by the SD of the pooled population at Baseline.
Based on Cohen’s recommendations, the following
values represent the magnitudes of responsiveness: small
change (SES = 0.20), moderate change (SES = 0.50), and
large change (SES = 0.80) [21]. Statistically significant
differences in change in scores between groups were
tested through an ANCOVA model adjusting for age,
sex, and race.
To demonstrate the application of MCT in responsive-
ness evaluation, unblinded cumulative distribution func-
tion (CDF) curves are presented, calculated as the
cumulative percentage of patients achieving various
threshold levels of change from Baseline in either the
overall average daily BMs or the average BMs during
Week 12 by treatment arm.
Results
A total of 135 patients were included in the ITT popula-
tion at baseline (Run-in Period), Day 1, and 120 patients
were included at Week 12. Baseline characteristics were
generally similar across all treatment groups [13]. The
numbers of patients with available PRO data at Week 12
by parameter were: n = 108 (90.0%) average daily BM;
n = 114 (95.0%) adequate relief; n = 113 (94.2%) EORTC
QLQ-C30; and n = 113 (94.2%) GI.NET21 data.
Interpretation of scores: meaningful change
Relationship between potential PRO anchors and BM
frequency
Only the QLQ-C30 Diarrhea symptom score yielded a
correlation coefficient with average BM frequency ex-
ceeding the acceptability threshold of > 0.30 at Week 12
(Pearson = 0.42; Spearman = 0.45). Correlation was at
least equal to the acceptability threshold for two items:
(1) between change from baseline in the QLQ-C30
Diarrhea symptom score at Week 12 and in overall BM
frequency (Pearson = 0.38; Spearman = 0.31); (2) and a
correlation between change from baseline in GI.NET21
GI Symptoms domain score at Week 12 and change
from baseline in overall BM frequency (Pearson = 0.30;
Spearman = 0.30).
Anchor-based analysis of meaningful overall change from
baseline in BM frequency
An anchor-based analysis of thresholds for meaningful
overall change in BM frequency produced a large ES
(defined as > 0.80) among ITT patients reporting ad-
equate relief at Week 12 (− 1.20), EORTC QLQ-C30
Diarrhea Symptom scale (− 0.83) and EORTC GI.NET21
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GI Symptoms scale (− 1.25) responders. Wilcoxon Rank
Sum test analysis indicated a significant difference in ad-
equate relief groups (P-value = 0.011), EORTC QLQ-C30
Diarrhea Symptoms domain (P-value = 0.019), and
EORTC GI.NET21 GI Symptoms domain responders
and non-responders (P-value < 0.001) (Table 1).
Large ES estimates were observed among ISP patients
whose perception of change was “a great deal better” (−
1.57) and “much better” (− 1.52), patients who reported
being “very satisfied” (− 1.30) and “somewhat dissatisfied”
(− 1.24) with symptom relief, the collapsed improvement
category for carcinoid symptom relief (− 0.93), and those
that considered their perception of change in BM fre-
quency to be clinically meaningful (− 0.99). Kruskal-Wallis
Exact test indicated a significant difference between the
perceptions of change in BMs response groups (P-value =
0.005) (Fig. 1).
Analysis of meaningful change in BM frequency at week 12
Anchor-based analysis indicated a large ES among ITT
patients who reported adequate relief at Week 12 (−
1.58), responders on the EORTC QLQ-C30 Diarrhea
domain (− 1.24), and the EORTC GI.NET21 GI Symptoms
Domain (− 1.49) (Table 1). Wilcoxon Rank Sum test
analysis indicated a significant difference in adequate relief
groups (P-value = 0.014), EORTC QLQ-C30 Diarrhea
Symptoms domain (P-value < 0.001), and EORTC
GI.NET21 GI Symptoms domain responders and non-
responders (P-value = 0.005).
A large ES was observed among ISP patients who re-
ported change of “A great deal better” and “Much bet-
ter” in BMs (− 1.97, − 1.83, respectively), patients who
improved in the collapsed perception categories (− 0.99),
patients who reported being “very satisfied” with the
relief (− 1.53), improved in the collapsed satisfaction
categories (− 1.23), and patients who reported their per-
ception of change in BM frequency clinically meaningful
(− 1.27) (Fig. 2). Kruskal-Wallis Exact test indicated a
significant difference between the perceptions of change
in BM response groups (P-value = 0.029).
Distribution-based thresholds
Overall, the thresholds for meaningful change in overall
average BM frequency at baseline and the change in
average BM frequency from baseline at Week 12 were
0.62 and 0.86 BM/day, respectively (Table 1).
Responsiveness
Responsiveness analysis suggested that change from
baseline in overall average BM frequency was moderately
responsive to patient reported changes (Table 2). There
were large reductions in average weekly BMs among pa-
tients indicating a change from “No” at baseline to “Yes”
in adequate relief at Week 12 (SES = − 0.99), patients
that indicated a great deal of improvement in BMs
(SES = − 1.44), and among patients who were “Very satis-
fied” (SES = − 1.18) with their relief. The number of ISP
patients stratified into the perception of change and sat-
isfaction with study medication response was sub-
optimal.
Responsiveness analysis indicated slightly greater re-
ductions in BM frequency from baseline at Week 12
when compared to change during the Double-blind
Treatment Period. Large negative SES values were ob-
served across several item response categories, includ-
ing patients who changed their response on the
adequate relief item to “Yes” at Week 12 as well as
those that continued to report “No” (SES = − 1.40 and
− 0.81, respectively), patients whose self-reported per-
ception of change was “A great deal better” (SES = −
1.80), and among patients who reported being “Very
satisfied” with their relief of CS symptoms (SES = −
1.38).
Cumulative distribution function curves in Figs. 3 and 4
show a clear separation of treatment and placebo at iden-
tified thresholds of meaningful change.
Table 1 Summary of Meaningful Change Thresholds
Parameter Threshold for
Acceptability
Analysis
Population
Average Number of Daily BMs
Overall Change from Baseline Change from Baseline at Week 12
N ES Mean N ES Mean
Anchor-based Meaningful Change Thresholds
Adequate relief (changed to Yes at Week 12) Effect Size:
-Small (≥ 0.2)
-Moderate (≥ 0.5)
-Large (≥ 0.8)
ITT 19 −1.20 −1.90 18 −1.58 −2.52
EORTC QLQ-C30 Diarrhea (Responder) ITT 45 −0.83 −1.71 40 −1.24 −2.56
EORTC GI.NET21 GI Symptoms (Responder) ITT 30 −1.25 −1.88 25 −1.49 −2.27
Distribution-based Meaningful Change Thresholds
−1/2 Baseline SD N/A ITT 135 N/A 0.62 108 N/A 0.86
BM Bowel movement, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire, ES Effect
size, ITT Intent-to-treat, N/A Not applicable, SD Standard deviation
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Discussion
Diarrhea is a prominent feature of CS, which may require
a different impact measurement approach than other
forms of diarrhea to understand clinically meaningful
change. A distribution-based method yielded meaningful
change estimates of 0.62 BM/day for overall BM frequency
and 0.83 BM/day at Week 12, indicating that patients
whose average BM frequency increased or decreased by
more than that level were reporting a meaningful change.
An anchor-based approach was developed using exit
interview data and change in scores. The QLQ-C30 Diar-
rhea Symptom and GI.NET21 GI Symptoms scale were
found to have an association > 0.3, and were thus used to
derive estimates of meaningful change. Specifically, change
from baseline in the QLQ-C30 Diarrhea symptom score
at Week 12 correlated with Change from baseline in Over-
all BM frequency at 0.38. When applying exit interview
data as the basis for meaningful change, patients’ percep-
tion of change in BMs since beginning the study yielded
ES estimates of − 1.57 for overall change during the
Double-blind Treatment Period and − 1.97 for change be-
tween baseline and Week 12.
When analyzing the responsiveness of BM fre-
quency to various levels of patient reported change,
ES estimates for the perception of change item for
both overall change and change from Week 12 were
significantly different despite the low subject num-
bers interviewed after the Double-blind Treatment
Period. The ES estimates (and the accompanying
threshold of − 1.97 BMs) could be valuable when ap-
proximating meaningful change in BM frequency.
When applying these thresholds to the clinical
change results in the CDF curves, the trend towards
greater reductions in BM frequency among the treat-
ment patients indicate a higher percentage would ex-
ceed the anchor and distribution-based thresholds,
although this would need to be confirmed as part of
an efficacy analysis.
Current clinical outcome assessment research has
demonstrated that it is possible to establish defensible
Fig. 1 Effect Sizes of Change in Overall BM Frequency from Baseline (ISP population)
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Fig. 2 Effect Sizes of Change in BM Frequency at Week 12 from Baseline (ISP population)
Table 2 Summary of Responsiveness Results
Parameter Threshold for
Acceptability
Analysis
Population
Average Daily BMs
Overall Change from
Baseline
Change from Baseline at Week
12
N SES N SES
Responsiveness (SES)
Adequate relief (changed to Yes at Week 12)a Standard Effect Size:
-Small (≥ 0.2)
-Moderate (≥ 0.5)
-Large (≥ 0.8)
ITT 19 −0.99 18 −1.40
Perception of change in BMsb
A great deal better ISP 9 −1.44 8 −1.80
Much better ISP 4 −0.50 4 −0.60
Satisfaction with study medication—Relief of CSc
Very satisfied ISP 12 −1.18 12 −1.38
Somewhat satisfied ISP 7 −0.15 6 −0.38
BM Bowel movement, CS Carcinoid syndrome, ISP Interview subpopulation, ITT Intent-to-treat, SES Standardized effect size
aThere were n = 75 “not changed to yes at Week 12”
bThere were n = 10 “a little better”; n = 10 “the same”; and n = 1 “a little worse”
cThere were n = 8 “neither satisfied nor dissatisfied”; n = 3 “somewhat dissatisfied”; and n = 3 “very satisfied”
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responder thresholds, which support informed treat-
ment decisions [22]. Some physicians interpret clinic-
ally meaningful change based on means: however, it
is important to examine the distribution of response
as in the CDF. The relevance of the CDF is reflected
by its inclusion in product labeling [23]. Figure 4
shows that some responders achieved reductions in
the range of 3 to 9 BMs/day on treatment, but not
on placebo. These are results averaged over 12-weeks,
corresponding to BM reductions during this time
frame.
A limitation is that a minimum change is difficult to
identify. The mean BM frequency change in a responder
group is not necessarily a minimum; it would be of
interest to examine empiric density distributions to see
which levels of BM frequency change distinguish be-
tween responders and non-responders.
Conclusions
Meaningful change derivation is critical for the inter-
pretation of patient outcomes in the evaluation of treat-
ment efficacy. Analyses identified a meaningful change
Fig. 3 CDF of Overall Change from Baseline in Average BM Frequency
Fig. 4 CDF of Change in Average BM Frequency from Baseline at Week 12
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in BM frequency which would coincide with improve-
ment across each of the patient reported anchors (retro-
spective and prospective). More specifically, CS patients
treated with telotristat ethyl experienced clinically mean-
ingful reductions in BM frequency of ≥30% over 12
weeks.
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